echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Circulation: Effect of Vericiguat on hemoglobin and clinical outcome of patients with heart failure with reduced ejection fraction

    Circulation: Effect of Vericiguat on hemoglobin and clinical outcome of patients with heart failure with reduced ejection fraction

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Vericiguat is an oral soluble guanylate cyclase (sGC) modulator, mainly used to treat patients with malignant chronic heart failure and reduced left ventricular ejection fraction (LVEF)
    .


    In the VICTORIA trial, patients treated with Vericiguat (7.


    Recently, the heart blood vessels published a research article in the authoritative magazine on the field of Circulation, the researchers aimed to investigate Vericiguat, randomized hemoglobin, the association between anemia, as well as the benefits of Vericiguat whether related to baseline hemoglobin
    .

    Heart blood vessels


    Anemia is defined as male hemoglobin <13.


    0g/dL and female <12.



    Anemia is common after Vericiguat treatment, and lower hemoglobin is associated with a higher frequency of clinical events


    Original source:

    Justin A.


    Ezekowitz,et al.
    Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA) .
    Circulation.
    2021.
    https:// 121.


    Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA) in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.